{"id":"tirofiban-oral-dual-antiplatelet-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tirofiban blocks the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and platelet cross-linking. When combined with oral dual antiplatelet therapy (typically aspirin and a P2Y12 inhibitor like clopidogrel), this creates a synergistic antiplatelet effect that reduces thrombotic complications in acute coronary syndromes and percutaneous coronary intervention.","oneSentence":"Tirofiban is a glycoprotein IIb/IIIa inhibitor combined with oral dual antiplatelet therapy to prevent platelet aggregation and thrombotic events through multiple antiplatelet pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:55.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)"},{"name":"Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI)"}]},"trialDetails":[{"nctId":"NCT05225961","phase":"PHASE4","title":"ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-05-01","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT07290751","phase":"PHASE4","title":"Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-11","conditions":"Acute Ischemic Stroke","enrollment":976},{"nctId":"NCT07095790","phase":"PHASE4","title":"Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-08-30","conditions":"Mild Stroke","enrollment":580},{"nctId":"NCT05902000","phase":"NA","title":"Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion","status":"UNKNOWN","sponsor":"Xueli Cai","startDate":"2023-06-14","conditions":"Thrombectomy, Tandem Occlusion, Stroke","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7980,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tirofiban with Sequential Dual Antiplatelet Therapy"],"phase":"marketed","status":"active","brandName":"Tirofiban+Oral Dual Antiplatelet Therapy","genericName":"Tirofiban+Oral Dual Antiplatelet Therapy","companyName":"Second Affiliated Hospital of Soochow University","companyId":"second-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tirofiban is a glycoprotein IIb/IIIa inhibitor combined with oral dual antiplatelet therapy to prevent platelet aggregation and thrombotic events through multiple antiplatelet pathways. Used for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), Prevention of thrombotic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}